Epidemiologic Relationships Between A1C and All-Cause Mortality During a Median 3.4-Year Follow-up of Glycemic Treatment in the ACCORD Trial
Open accessThe DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Randomized treatment comparing an intensive glycemic treatment strategy with a standard strategy in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial was ended early because of an unexpected excess of mortality in the intensive arm. As part of ongoing post hoc analyses of potential mechanisms for this finding, we explored whether on-treatment A1C itself had an independent relationship with mortality. RESEARCH DESIGN AND METHODS: Participants with type 2 diabetes (n = 10,251 with mean age 62 years, median duration of diabetes 10 years, and median A1C 8.1%) were randomly assigned to treatment strategies targeting either A1C <6.0% (intensive) or A1C 7.0–7.9% (standard). Data obtained during 3.4 (median) years of follow-up before cessation of intensive treatment were analyzed using several multivariable models. RESULTS: Various characteristics of the participants and the study sites at baseline had significant associations with the risk of mortality. Before and after adjustment for these covariates, a higher average on-treatment A1C was a stronger predictor of mortality than the A1C for the last interval of follow-up or the decrease of A1C in the first year. Higher average A1C was associated with greater risk of death. The risk of death with the intensive strategy increased approximately linearly from 6–9% A1C and appeared to be greater with the intensive than with the standard strategy only when average A1C was >7%. CONCLUSIONS: These analyses implicate factors associated with persisting higher A1C levels, rather than low A1C per se, as likely contributors to the increased mortality risk associated with the intensive glycemic treatment strategy in ACCORD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The potential risks of intensive glycemic control may be obviated by incorporating agents that are not associated with hypoglycemia, especially in persons with frequent severe hypoglycemia, hypoglycemia unawareness, or a very long duration of DM, and particularly in the presence of established and advanced atherosclerosis, advanced age, and terminal illness.69,70,76–81”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [80]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A corollary of this issue is the safety of those therapies in view of the demonstrated increase of frequency of severe hypoglycemia during attempts at intensive glycemic control.70,76,80,85,86”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [80]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“These trials have more or less uniformly demonstrated a benefit, with lifestyle more efficacious than all medications with the exception of the thiazolidinediones140–152.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [148]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · cited 1×
“This association, not taking into consideration the glycemic treatment strategy, is similar to the 12 and 14% increments of mortality associated with 1% higher average A1C in epidemiologic analyses from other studies (6,19).”
ResultEffects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Stamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
Flexible smoothing with B-splines and penalties
Eilers, P. H. C., & Marx, B. D. (1996) · Statistical Science · doi:10.1214/ss/1038425655 · Cited by 3,666 · cited 1×
“Curves modeling the relationships over the range of observed A1C values (penalized B-splines) (17,18) were used to explore the linearity assumption in the Cox proportional hazards model.”
MethodDiabetes and Cardiovascular Disease: The Framingham Study
Kannel, W. B. (1979) · JAMA · doi:10.1001/jama.1979.03290450033020 · Cited by 2,936
Coutinho, M., Gerstein, H. C., Wang, Y., & Yusuf, S. (1999) · Diabetes Care · doi:10.2337/diacare.22.2.233 · Cited by 1,685
Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus
Selvin, E., Marinopoulos, S., Berkenblit, G., Rami, T., Brancati, F. L., Powe, N. R., & Golden, S. H. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-6-200409210-00007 · Cited by 1,657
Hurvich, C. M., Simonoff, J. S., & Tsai, C.-L. (1998) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00125 · Cited by 1,241 · cited 1×
“Curves modeling the relationships over the range of observed A1C values (penalized B-splines) (17,18) were used to explore the linearity assumption in the Cox proportional hazards model.”
MethodSkyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A. M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., et al. (2009) · Diabetes Care · doi:10.2337/dc08-9026 · Cited by 881
Self-citation
Cited by
Oxidative stress and diabetic complications
Giacco, F., & Brownlee, M. (2010) · Circulation Research · doi:10.1161/circresaha.110.223545 · Cited by 5,461
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
“Unlike the DCCT, where lower achieved A1C levels were related to significantly increased rates of severe hypoglycemia, in ACCORD every 1% decline in A1C from baseline to 4 months into the trial was associated with a significant decrease in the rate of severe hypoglycemia in both arms (95).”
BackgroundStandards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Standards of medical care in diabetes—2011
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s011 · Cited by 2,880
Chatterjee, S., Khunti, K., & Davies, M. J. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30058-2 · Cited by 2,577
Standards of Medical Care in Diabetes—2012
(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62154-6 · Cited by 1,743
Low Wang, C. C., Hess, C. N., Hiatt, W. R., & Goldfine, A. B. (2016) · Circulation · doi:10.1161/circulationaha.116.022194 · Cited by 1,155
Long-term effects of intensive glucose lowering on cardiovascular outcomes
The ACCORD Study Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1006524 · Cited by 1,035
Achievement of Goals in U.S. Diabetes Care, 1999–2010
Ali, M. K., Bullard, K. M., Saaddine, J. B., Cowie, C. C., Imperatore, G., & Gregg, E. W. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1213829 · Cited by 979
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2016) · Endocrine Practice · doi:10.4158/ep151126.cs · Cited by 878
“The excess mortality occurred only in patients whose A1C remained >7% despite intensive therapy, whereas in the standard therapy group (A1C target 7 to 8%), mortality followed a U-shaped curve with increasing death rates at both low (<7%) and high (>8%) A1C levels (76).”
BackgroundHandelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Garber, A. J., Handelsman, Y., Grunberger, G., Einhorn, D., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bush, M. A., DeFronzo, R. A., Garber, J. R., et al. (2020) · Endocrine Practice · doi:10.4158/cs-2019-0472 · Cited by 598
Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline
LeRoith, D., Biessels, G. J., Braithwaite, S. S., Casanueva, F. F., Draznin, B., Halter, J. B., Hirsch, I. B., McDonnell, M. E., Molitch, M. E., Murad, M. H., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00198 · Cited by 568
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Bozkurt, B., Aguilar, D., Deswal, A., Dunbar, S. B., Francis, G. S., Horwich, T., Jessup, M., Kosiborod, M., Pritchett, A. M., Ramasubbu, K., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000450 · Cited by 522
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2018) · Endocrine Practice · doi:10.4158/cs-2017-0153 · Cited by 502
Bariatric surgery: an IDF statement for obese Type 2 diabetes
Dixon, J. B., Zimmet, P., Alberti, K. G., Rubino, F., & on behalf of the International Diabetes Federation Taskforce on Epidemiology and Prevention (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03306.x · Cited by 494
Fox, C. S., Golden, S. H., Anderson, C., Bray, G. A., Burke, L. E., de Boer, I. H., Deedwania, P., Eckel, R. H., Ershow, A. G., Fradkin, J., et al. (2015) · Diabetes Care · doi:10.2337/dci15-0012 · Cited by 492
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2017) · Endocrine Practice · doi:10.4158/ep161682.cs · Cited by 435
“The excess mortality occurred only in patients whose A1C remained >7% despite intensive therapy, while in the standard therapy group (A1C target 7 to 8%), mortality followed a U-shaped curve with increasing death rates at both low (<7%) and high (>8%) A1C levels (79).”
BackgroundFox, C. S., Golden, S. H., Anderson, C., Bray, G. A., Burke, L. E., de Boer, I. H., Deedwania, P., Eckel, R. H., Ershow, A. G., Fradkin, J., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000230 · Cited by 386
Hypoglycemia and cardiovascular risks
Frier, B. M., Schernthaner, G., & Heller, S. R. (2011) · Diabetes Care · doi:10.2337/dc11-s220 · Cited by 381
“Thus, the ACCORD investigators concluded that symptomatic severe hypoglycemia does not appear to account for the difference in mortality between the two arms of the study up to the time when the ACCORD intensive glycemia arm was discontinued (43).”
BackgroundCradock, K. A., ÓLaighin, G., Finucane, F. M., Gainforth, H. L., Quinlan, L. R., & Ginis, K. A. M. (2017) · International Journal of Behavioral Nutrition and Physical Activity · doi:10.1186/s12966-016-0436-0 · Cited by 343
“9 % [29] therefore HbA1c levels >8 % represent poorly controlled type 2 diabetes.”
BackgroundGlycemic Control, Complications, and Death in Older Diabetic Patients
Huang, E. S., Liu, J. Y., Moffet, H. H., John, P. M., & Karter, A. J. (2011) · Diabetes Care · doi:10.2337/dc10-2377 · Cited by 343
Contributions of risk factors and medical care to cardiovascular mortality trends
Ezzati, M., Obermeyer, Z., Tzoulaki, I., Mayosi, B. M., Elliott, P., & Leon, D. A. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.82 · Cited by 338
The importance of weight management in type 2 diabetes mellitus
Wilding, J. P. H. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12384 · Cited by 314
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2019) · Endocrine Practice · doi:10.4158/cs-2018-0535 · Cited by 297
“In the standard therapy group (A1C target 7 to 8% [53 to 64 mmol/mol]), mortality followed a U-shaped curve with increasing death rates at both low (<7%) and high (>8%) A1C levels (177).”
BackgroundLu, J., Wang, C., Shen, Y., Chen, L., Zhang, L., Cai, J., Lu, W., Zhu, W., Hu, G., Xia, T., et al. (2021) · Diabetes Care · doi:10.2337/dc20-1862 · Cited by 282
HbA1c and Risk of Severe Hypoglycemia in Type 2 Diabetes
Lipska, K. J., Warton, E. M., Huang, E. S., Moffet, H. H., Inzucchi, S. E., Krumholz, H. M., & Karter, A. J. (2013) · Diabetes Care · doi:10.2337/dc13-0610 · Cited by 246
Hempe, J. M., Liu, S., Myers, L., McCarter, R. J., Buse, J. B., & Fonseca, V. (2015) · Diabetes Care · doi:10.2337/dc14-1844 · Cited by 233
Self-citationContinuous Glucose Monitoring Systems: A Review
Vashist, S. (2013) · Diagnostics · doi:10.3390/diagnostics3040385 · Cited by 261
Association between adherence to pharmacotherapy and outcomes in type 2 diabetes: a meta-analysis
Khunti, K., Seidu, S., Kunutsor, S., & Davies, M. (2017) · Diabetes Care · doi:10.2337/dc16-1925 · Cited by 231
“improved glycemic control given the established relationship between hyperglycemia andmortality (41).”
BackgroundCardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes
Holman, R. R., Sourij, H., & Califf, R. M. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60794-7 · Cited by 227
Nolan, C. J., Ruderman, N. B., Kahn, S. E., Pedersen, O., & Prentki, M. (2015) · Diabetes · doi:10.2337/db14-0694 · Cited by 226
Papademetriou, V., Lovato, L., Doumas, M., Nylen, E., Mottl, A., Cohen, R. M., Applegate, W. B., Puntakee, Z., Yale, J. F., & Cushman, W. C. (2015) · Kidney International · doi:10.1038/ki.2014.296 · Cited by 210
Self-citationPrimary Prevention of Cardiovascular Disease in Diabetes Mellitus
Newman, J. D., Schwartzbard, A. Z., Weintraub, H. S., Goldberg, I. J., & Berger, J. S. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.07.001 · Cited by 205
“Reasons for the increased mortality associated with intensive glucose control in the ACCORD trial are unclear and are discussed in detail elsewhere (64,65).”
BackgroundMaahs, D. M., Daniels, S. R., de Ferranti, S. D., Dichek, H. L., Flynn, J., Goldstein, B. I., Kelly, A. S., Nadeau, K. J., Martyn-Nemeth, P., Osganian, S. K., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000094 · Cited by 194
Nine-year effects of 3.7 years of intensive glycemic control on cardiovascular outcomes
The ACCORD Study Group (2016) · Diabetes Care · doi:10.2337/dc15-2283 · Cited by 193
Wayne, N., Perez, D. F., Kaplan, D. M., & Ritvo, P. (2015) · Journal of Medical Internet Research · doi:10.2196/jmir.4871 · Cited by 192
Johnston, S. S., Conner, C., Aagren, M., Smith, D. M., Bouchard, J., & Brett, J. (2011) · Diabetes Care · doi:10.2337/dc10-1915 · Cited by 189
Guideline for management of postmeal glucose in diabetes
(2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.08.002 · Cited by 183
Insulin therapy and hypoglycemia
McCall, A. L. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.03.001 · Cited by 177
Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges?
Home, P., Riddle, M., Cefalu, W. T., Bailey, C. J., Bretzel, R. G., del Prato, S., Leroith, D., Schernthaner, G., van Gaal, L., & Raz, I. (2014) · Diabetes Care · doi:10.2337/dc13-2743 · Cited by 167
“an intensive treatment regimen correlated with risk of excess mortality (50).”
BackgroundSelf-citationThe impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study
Seaquist, E. R., Miller, M. E., Bonds, D. E., Feinglos, M., Goff, D. C., Peterson, K., Senior, P., & for the ACCORD Investigators (2012) · Diabetes Care · doi:10.2337/dc11-0996 · Cited by 131
Self-citationHypoglycemia, Diabetes, and Cardiovascular Disease
Snell-Bergeon, J. K., & Wadwa, R. P. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0031 · Cited by 161
Severe Hypoglycemia Predicts Mortality in Diabetes
Cryer, P. E. (2012) · Diabetes Care · doi:10.2337/dc12-0749 · Cited by 158
Breaking Down Patient and Physician Barriers to Optimize Glycemic Control in Type 2 Diabetes
Ross, S. A. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.06.012 · Cited by 172
Insulin Therapy for Type 2 Diabetes Mellitus
Wallia, A., & Molitch, M. E. (2014) · JAMA · doi:10.1001/jama.2014.5951 · Cited by 153
Ratner, R., Han, J., Nicewarner, D., Yushmanova, I., Hoogwerf, B. J., & Shen, L. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-22 · Cited by 153
Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes
Ross, S. A., Tildesley, H. D., & Ashkenas, J. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.621416 · Cited by 150
Gerstein, H. C., Miller, M. E., Ismail-Beigi, F., Largay, J., McDonald, C., Lochnan, H. A., & Booth, G. L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60611-5 · Cited by 151
Gaps and barriers in the control of blood glucose in people with type 2 diabetes
Blonde, L., Aschner, P., Bailey, C., Ji, L., Leiter, L. A., Matthaei, S., & Management, O. B. O. T. G. P. F. E. D. (2017) · Diabetes and Vascular Disease Research · doi:10.1177/1479164116679775 · Cited by 146
Personalized Management of Hyperglycemia in Type 2 Diabetes
Raz, I., Riddle, M. C., Rosenstock, J., Buse, J. B., Inzucchi, S. E., Home, P. D., Del Prato, S., Ferrannini, E., Chan, J. C. N., Leiter, L. A., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0512 · Cited by 143
Self-citationDeath during intensive glycemic therapy of diabetes: mechanisms and implications
Cryer, P. E. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.08.008 · Cited by 137
Cavagnolli, G., Pimentel, A. L., Freitas, P. A. C., Gross, J. L., & Camargo, J. L. (2017) · PLOS ONE · doi:10.1371/journal.pone.0171315 · Cited by 138
Bariatric surgery: an IDF statement for obese Type 2 diabetes
Dixon, J. B., Zimmet, P., Alberti, K. G. M. M., & Rubino, F. (2011) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2011.05.013 · Cited by 146
From Hong Kong Diabetes Register to JADE Program to RAMP-DM for Data-Driven Actions
Chan, J. C. N., Lim, L.-L., Luk, A. O. Y., Ozaki, R., Kong, A. P. S., Ma, R. C. W., So, W.-Y., & Lo, S.-V. (2019) · Diabetes Care · doi:10.2337/dci19-0003 · Cited by 133
Imran, S. A., RABASA-LHORET, R. P. R., & Ross, S. A. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.016 · Cited by 148
9. Microvascular Complications and Foot Care
American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc16-s012 · Cited by 172
Rothschild, S. K., Martin, M. A., Swider, S. M., Tumialán Lynas, C. M., Janssen, I., Avery, E. F., & Powell, L. H. (2014) · American Journal of Public Health · doi:10.2105/ajph.2013.301439 · Cited by 129
Miller, M. E., Williamson, J. D., Gerstein, H. C., Byington, R. P., Cushman, W. C., Ginsberg, H. N., Ambrosius, W. T., Lovato, L., Applegate, W. B., & for the ACCORD Investigators (2014) · Diabetes Care · doi:10.2337/dc13-1545 · Cited by 129
Self-citationBakris, G. L. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0713 · Cited by 145
“A post hoc analysis of the ACCORD data conducted to explore this finding showed that a higher average on-treatment HbA 1c was a strong predictor of death.(63) In the intensive therapy arm, the mortality risk increased approximately linearly over an average HbA 1c range of 6.”
Method9. Microvascular Complications and Foot Care
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc15-s012 · Cited by 137
Insulin Therapy Increases Cardiovascular Risk in Type 2 Diabetes
Herman, M. E., O’Keefe, J. H., Bell, D. S. H., & Schwartz, S. S. (2017) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2017.09.001 · Cited by 130
Palta, P., Huang, E. S., Kalyani, R. R., Golden, S. H., & Yeh, H.-C. (2017) · Diabetes Care · doi:10.2337/dci16-0042 · Cited by 116
Kahal, H., Halama, A., Aburima, A. A., Bhagwat, A. M., Butler, A. E., Graumann, J., Suhre, K., Sathyapalan, T., & Atkin, S. L. (2020) · Scientific Reports · doi:10.1038/s41598-020-61531-z · Cited by 122
Giorgino, F., Leonardini, A., & Laviola, L. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12044 · Cited by 118
Glucose targets for preventing diabetic kidney disease and its progression
Ruospo, M., Saglimbene, V. M., Palmer, S. C., De Cosmo, S., Pacilli, A., Lamacchia, O., Cignarelli, M., Fioretto, P., Vecchio, M., Craig, J. C., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010137.pub2 · Cited by 111
Bosi, E., Scavini, M., Ceriello, A., Cucinotta, D., Tiengo, A., Marino, R., Bonizzoni, E., Giorgino, F., & on behalf of the PRISMA Study Group (2013) · Diabetes Care · doi:10.2337/dc13-0092 · Cited by 105
Riddle, M. C. (2010) · Circulation · doi:10.1161/circulationaha.110.960138 · Cited by 110
Self-citationWe Can Change the Natural History of Type 2 Diabetes
Phillips, L. S., Ratner, R. E., Buse, J. B., & Kahn, S. E. (2014) · Diabetes Care · doi:10.2337/dc14-0817 · Cited by 103
“0% (53 mmol/mol) (77), and increased mortality was not found in subgroups who were earlier in”
BackgroundSelf-citationInsulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease
Lo, C., Toyama, T., Wang, Y., Lin, J., Hirakawa, Y., Jun, M., Cass, A., Hawley, C. M., Pilmore, H., Badve, S. V., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011798.pub2 · Cited by 100
Laiteerapong, N., Karter, A. J., Moffet, H. H., Cooper, J. M., Gibbons, R. D., Liu, J. Y., Gao, Y., & Huang, E. S. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.07.023 · Cited by 101
“%) were associated with a 64% increased mortality rate after 3 years (Riddle et al., 2010).”
Terry, T., Raravikar, K., Chokrungvaranon, N., & Reaven, P. D. (2011) · Current Cardiology Reports · doi:10.1007/s11886-011-0238-6 · Cited by 103
Cardiac implications of hypoglycaemia in patients with diabetes – a systematic review
Hanefeld, M., Duetting, E., & Bramlage, P. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-135 · Cited by 93
“Thus, it remains plausible that hypoglycaemia could have influenced the results observed in the ACCORD trial since it is difficult to reliably assign the potential contribution of hypoglycaemia to these deaths.”
BackgroundMethodInfluentialIntensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes Mellitus
Kirkman, M. S., Mahmud, H., & Korytkowski, M. T. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.002 · Cited by 95
Management of diabetes in older adults
Sesti, G., Antonelli Incalzi, R., Bonora, E., Consoli, A., Giaccari, A., Maggi, S., Paolisso, G., Purrello, F., Vendemiale, G., & Ferrara, N. (2018) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.11.007 · Cited by 84
Tandon, N., Ali, M. K., & Narayan, K. M. V. (2012) · American Journal of Cardiovascular Drugs · doi:10.2165/11594650-000000000-00000 · Cited by 107
“non-responders) glucose levels, rather than lowering of these levels in the trial, may have been responsible for the higher mortality rate in the intensive therapy group.([20]) Importantly, however, the primary outcome rates were lower than predicted, with the standard therapy arm showing an annual rate of 2.”
ResultShao, H., Fonseca, V., Stoecker, C., Liu, S., & Shi, L. (2018) · PharmacoEconomics · doi:10.1007/s40273-018-0662-1 · Cited by 85
The trials and tribulations of determining HbA1c targets for diabetes mellitus
Klein, K. R., & Buse, J. B. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00425-6 · Cited by 97
Self-citationIs Hyperglycemia a Cardiovascular Risk Factor?
Pistrosch, F., Natali, A., & Hanefeld, M. (2011) · Diabetes Care · doi:10.2337/dc11-s207 · Cited by 81
Wang, C. C. L., & Reusch, J. E. B. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.08.036 · Cited by 82
Zhao, B., Zeng, L., Zhao, J., Wu, Q., Dong, Y., Zou, F., Gan, L., Wei, Y., & Zhang, W. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-032240 · Cited by 87
Andersson, C., Gaal, L. V., Caterson, I. D., Weeke, P. E., James, W. P. T., Couthino, W., Finer, N., Sharma, A. M., Maggioni, A. P., & Torp-Pedersen, C. T. (2012) · Diabetologia · doi:10.1007/s00125-012-2584-3 · Cited by 87
“Interestingly, post hoc analyses indicated that the risk was not associated with low HbA1c as such, but was rather driven by a high risk for those who failed to achieve a low HbA1c, which may have been due to factors such as weight gain; this is nevertheless not well investigated [21].”
on behalf of the ADVANCE Collaborative Group, van Steen, S. C. J., Woodward, M., Chalmers, J. P., Li, Q., Marre, M., Cooper, M. E., Hamet, P., Mancia, G., Colagiuri, S., et al. (2018) · Diabetologia · doi:10.1007/s00125-017-4539-1 · Cited by 87
“Post hoc, it was shown that intensively treated ACCORD participants with a high average on-treatment HbA1c (>53 mmol/ mol [>7%]) were at greater risk for mortality than intensively treated participants with average HbA1c <53mmol/mol (<7%) or standard-treated individuals with average HbA1c >53 mmol/mol (>7%) [27].”
BackgroundThe ORIGIN Trial Investigators (2015) · Diabetes Care · doi:10.2337/dc14-1329 · Cited by 75
Basu, S., Raghavan, S., Wexler, D. J., & Berkowitz, S. A. (2017) · Diabetes Care · doi:10.2337/dc17-2252 · Cited by 80
Skriver, M. V., Sandbæk, A., Kristensen, J. K., & Støvring, H. (2015) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2014-000060 · Cited by 71
“34 The ACCORD study found no association between mortality and change in HbA1c in the standard treatment group, but demonstrated an increased mortality in the intensively treated group for participants whose HbA1c declined little or not at all.”
BackgroundImpact of lower achieved blood pressure on outcomes in hypertensive patients
Okin, P. M., Hille, D. A., Kjeldsen, S. E., Dahlöf, B., & Devereux, R. B. (2012) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283516499 · Cited by 70
“Further analyses demonstrated that higher risk in the intensive treatment arm was associated with less reduction in HbA1c from baseline levels during the first 4–12 months of treatment [38,39].”
BackgroundType 2 diabetes mellitus—current therapies and the emergence of surgical options
Lebovitz, H. E. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.10 · Cited by 73
“Consequently, single agents and combination therapies are able to achieve target glycemic goals for limited periods of time and only in a subset of patients with T2DM”
BackgroundBianchi, C., & Prato, S. D. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.432 · Cited by 70
Recent HbA1c Values and Mortality Risk in Type 2 Diabetes. Population-Based Case-Control Study
Nicholas, J., Charlton, J., Dregan, A., & Gulliford, M. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068008 · Cited by 66
“The findings of the present study also appear to be consistent with those found in the ACCORD and VADT trials [29,30].”
ResultPreoperative Glycosylated Hemoglobin: A Risk Factor for Patients Undergoing Coronary Artery Bypass
Narayan, P., Kshirsagar, S., Mandal, C. K., Ghorai, P. A., Rao, Y. M., Das, D., Saha, A., Chowdhury, S. R., Rupert, E., & Das, M. (2017) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2016.12.020 · Cited by 68
Standl, E., Stevens, S. R., Lokhnygina, Y., Bethel, M. A., Buse, J. B., Gustavson, S. M., Maggioni, A. P., Mentz, R. J., Hernandez, A. F., & Holman, R. R. (2020) · Diabetes Care · doi:10.2337/dc19-1079 · Cited by 65
Self-citationCardiovascular Disease in Diabetes: Where Does Glucose Fit In?
Reusch, J. E. B., & Wang, C. C. L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-3011 · Cited by 68
O’Keefe, J. H., Abuannadi, M., Lavie, C. J., & Bell, D. S. H. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0434 · Cited by 65
“Yet, on detailed scrutiny of the data, higher HbA 1c values predicted increased risk of death in the intensive arm of the ACCORD trial, in which most of the deaths occurred in the subgroup of patients whose HbA 1c values remained high despite attempted intensive glycemic control.(12) MoreFIGURE 1.”
BackgroundVaag, A., & Lund, S. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-0022 · Cited by 62
Effects of Hypoglycemia on Cardiovascular Function in Patients with Diabetes
Christou, M., Christou, P. A., Kyriakopoulos, C., Christou, G. A., & Tigas, S. K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119357 · Cited by 71
“Although this study demonstrated increased hypoglycemia risk in the intensive treatment group, further analysis concluded that hypoglycemia did not appear to account for the difference in mortality between the two groups [69,70].”
Result
Metadata
- Authors
- Riddle, M. C., Ambrosius, W. T., Brillon, D. J., Buse, J. B., Byington, R. P., Cohen, R. M., Goff, D. C., Malozowski, S., Margolis, K. L., Probstfield, J. L., Schnall, A., Seaquist, E. R., & for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Investigators
- Affiliations
- Oregon Health & Science University (US)
- Wake Forest University Health Sciences (US)
- Cornell University (US)
- University of North Carolina at Chapel Hill (US)
- University of Cincinnati (US)
- National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland;
- HealthPartners (US)
- University of Washington (US)
- Case Western Reserve University (US)
- University of Minnesota (US)
- Corresponding author
- Riddle, Matthew C.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2010-05-01
- Volume
- 33
- Issue
- 5
- Pages
- 983-990
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2858202
- OpenAlex
- W2078241682
- Cited by
- 406
- References
- 21
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 9 · 2023: 12 · 2022: 13 · 2021: 13 · 2020: 18 · 2019: 25 · 2018: 26 · 2017: 31 · 2016: 27 · 2015: 37 · 2014: 28 · 2013: 30 · 2012: 40
- FWCI
- 38.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- National Institutes of Health (n01hc95183-23-0-0, n01hc95180-24-0-1, n01hc95184-24-0-1, n01hc95181-23-0-1, n01hc95182-23-0-1, n01hc95178-28-0-1, n01hc95179-25-0-0)
- National Heart, Lung, and Blood Institute (N01- HC-95181, N01 HC095184, N01-HC- 95180, N01-HC-95178, N01 HC095182, N01 HC095181, Y01 HC001010, N01-HC-095183, N01 HC095178, N01-HC-95184, N01HC95179, IAAY1-HC-1010, IAA #Y1-HC-9035, N01 HC095180, Y01 HC009035, N01‐HC‐95183, N01-HC-95182, N01 HC095179)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- HbA1c, all-cause mortality, tight glycemic control, type 2 diabetes, ACCORD trial, mortality risk
- MeSH terms
- Aged, Cause of Death, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hyperglycemia, Hypoglycemic Agents, Male, Middle Aged, Risk Factors, Multivariate Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.